We wanted to thank your office for meeting with us in February to discuss the issue of copay accumulator programs. As you may recall, on March 9, 2020, you and your cc’ed colleagues signed a letter to the U.S. Department of Health and Human Services (HHS), expressing concern over the 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule, which provides health plans with broad authority to implement copay accumulator programs. On behalf of patients throughout the country, we wanted to sincerely thank you for sending that letter and provide you with an update on the status of the rule.
Categories
- Actions
- Copay Accumulators
- Copay Assistance
- COVID-19
- Drug Costs
- Featured
- Federal Issues
- Health Insurance
- ICER
- Issues
- Letters Submitted
- Letters Supported
- Medicaid
- Medicare
- Medicare Part D
- News
- Op-Ed
- Out of Pocket Costs
- Pharmacy Benefit Managers
- Podcast
- QALY
- State Issues
- Step Therapy
- Uncategorized
- Value Frameworks
Tags
340B
Access
chemo drugs
cms
congress
Copay Accumulators
copay assistance
deferred action
DPC
drug costs
drug discount programs
Drug Importation
Drug Pricing
drug rebate
Elizabeth Warren
fail first
Federal Issues
Health Insurance
hospital bills
HR 3
HR 3708
hsa
ICER
immigration
Imported Drugs
Insurance design
Massachusetts
Medicaid
medicare part D
Nonmedical Switching
open enrollment
out of
Out of Pocket Costs
Patient Access
patient assistance programs
Patients Assitance
PBM
pharmacy
pharmacy benefit managers
Preexisting Conditions
Prior Authorization
QALY
Step Therapy
transparency
Value Framework
Recent Posts
- Recent Policy Changes in the 2021 Notice of Benefit and Payment Parameters (NBPP)
- Request that Co-pay Assistance Remain Allowable Permanently Under Massachusetts State Law
- Episode 19: Prescription Price Transparency
- Episode 18: Covid-19 Exposes Racial Disparities in the Healthcare System
- Reimbursement and Policy Changes Needed to Reduce Osteoporosis-Related Fractures